| 100062 |
Phase 4 |
A Randomized, Parallel Group, Double-Blind, Comparative Trial Assessing Lung Function and Other Measures of Asthma Control in Adults and Adolescents, at least 12 Years of Age, with Asthma, Who Have Either a B16-Arg/Arg, a B16-Gly/Gly or a B16-Arg/Gly Genotype (1 citation(s)) |
|
| 100250 |
Phase 4 |
A Randomized, Double-Blind, Parallel-Group, 52-Week Study to Compare the Effect of Fluticasone Propionate/Salmeterol DISKUS 250/50mcg BID with Salmeterol DISKUS 50mcg BID on the Annual Rate of Moderate/Severe Exacerbations in Subjects with Chronic Obstructive Pulmonary Disease (COPD) (1 citation(s)) |
|
| 100456 |
Phase 4 |
Pilot study: A Single-Centre, Randomised, Open-Label, Cross Over Trial, Assessing Ease of use, Correctness of use and Patient Preference of Seretide (Salmeterol Xinafoate/Fluticasone Propionate Combination) via the Diskus versus Seretide via the Metered Dose Inhaler in Subjects at Least 55 Years ... (0 citation(s)) |
|
| 100470 |
Phase 3 |
A multicentre, randomised, double-blind, parallel group, 24-week study to compare the effect of the salmeterol/fluticasone propionate combination product 50/250mcg, with salmeterol 50mcg both delivered twice daily via the DISKUS/ACCUHALER inhaler on lung function and dyspnoea in subjects with Ch ... (0 citation(s)) |
|
| 100540 |
Phase 3 |
A multi-centre, randomised, double-blind, parallel group study to investigate the efficacy and safety of the Salmeterol/fluticasone propionate combination at a strength of 50/500µg BD, compared with placebo via Accuhaler, added to usual COPD therapy, in subjects with COPD for 24 weeks (0 citation(s)) |
|
| 100614 |
phase 4 |
SUccessful Control and Clinical Effectiveness of SERETIDE study in aSthma, a randomised controlled study to investigate the clinical effectiveness and health outcome of SERETIDE in patients with moderate and severe persistent asthma in Korea (1 citation(s)) |
|
| 100807 |
Phase 1 |
Randomised, open label, two period, crossover study to compare the steroid systemic exposure of Fluticasone Propionate (FP) from FP/Salmeterol (SALM) (500/50) DISKUS and Budesonide (BUD) from BUD/formoterol (FOR).(200/6) Turbuhaler in patients with severe Chronic Obstructive Pulmonary Disease. (0 citation(s)) |
|
| 101877 |
Phase 1 |
A randomised, open label, 5-way crossover study to assess the systemic exposure of FP and salmeterol from SERETIDE/ADVAIR 250 without spacer, with Aerochamber -Plus and with -Max spacer, with VOLUMATIC spacer and SERETIDE/ADVAIR 500 DISKUS/ACCUHALER in adult subjects with mild or intermittent asthma (0 citation(s)) |
|
| 102318 |
Phase 4 |
Steroid-sparing management of the salmeterol/fluticasone 50/100µg b.i.d. combination compared to fluticasone 200µg b.i.d. in children and adolescents with moderate asthma (0 citation(s)) |
|
| 104962 |
Phase 2 |
A randomized, double-blind, double dummy, 3 way cross-over study evaluating the effects of SERETIDE™ 50/500mcg twice daily plus tiotropium bromide 18mcg once daily compared with the individual treatments (tiotropium bromide 18mcg alone and SERETIDE™ 50/500mcg alone) in the treatment of COPD. (2 citation(s)) |
|
| 108835 |
Phase 4 |
An Open Label, Multicentre Study to Evaluate Patient Satisfaction with Fluticasone/Salmeterol HFA MDI with Counter in Adult Subjects (18 years of age and older) with Asthma or COPD. (0 citation(s)) |
|
| 109315 |
Phase 4 |
A Retrospective Study of Healthcare Utilization and Costs of Step-Down Therapy in Asthma Patients Receiving Fluticasone Propionate/Salmeterol Combination (0 citation(s)) |
|
| 110099 |
Phase 3 |
A study to compare GW815SF HFA MDI with concomitant treatment with salmeterol xinafoate DPI plus fluticasone propionate DPI and to assess long-term safety of GW815SF HFA MDI (0 citation(s)) |
|
| 110101 |
Phase 3 |
Clinical assessment of GW815SF HFA MDI in pediatric patients with bronchial asthma
-A long term (24-week) study- (0 citation(s)) |
|
| 111114 |
phase 4 |
A 24-Week Study to Evaluate the Safety and Efficacy of ADVAIR DISKUS 250/50mcg Plus SPIRIVA HANDIHALER Versus SPIRIVA HANDIHALER Plus Placebo DISKUS in Subjects with Chronic Obstructive Pulmonary Disease (COPD). SPIRIVA and HANDIHALER are trade marks of Boehringer Ingelheim
(0 citation(s)) |
|
| 111117 |
Phase 4 |
A Randomized, Double-Blind, Double-Dummy, Parallel Group 12-Week Comparison of the Efficacy and Safety of Fluticasone Propionate/Salmeterol Hydrofluoroalkane 134a Metered-Dose-Inhaler 230/42mcg twice-daily with Fluticasone Propionate/Salmeterol DISKUS 250/50mcg twice-daily in subjects with COPD (0 citation(s)) |
|
| 111984_1 |
N/A |
The Asthma Death Case Control Study (ADCCS): Association between Recent Medication Use and Asthma Mortality (0 citation(s)) |
|
| 111985_1 |
N/A |
The long-term use of Advair/Seretide and risk of events (incident non-vertebral fracture, glaucoma, and cataracts) among COPD patients in the UK General Research Practice Database (0 citation(s)) |
|
| 112708 |
Phase 4 |
Control of Asthma With Addition of Long-Acting Beta-Agonists to Inhaled Corticosteroid Regimens
Systematic Review A Meta-analysis of Observational Studies
(0 citation(s)) |
|
| 112876_1 |
N/A |
A population-based observational study examining the incidence of pneumonia among COPD patients using Advair® (0 citation(s)) |
|
| 113642 |
N/ |
Seretide Evohaler PEM study (1 citation(s)) |
|
| 113656_1 |
N/A |
Advair use and risk of COPD hospitalization or mortality in US HMO network (1 citation(s)) |
|
| 113672_1 |
N/A |
Project Title: Assessment of the risk of pneumonia among COPD Patients on Seretide or Inhaled Corticosteroids in the UK primary care (0 citation(s)) |
|
| 207499/125 |
Phase 3 |
A Randomized, 12-Week, Double-blind, Placebo-controlled, Parallel-group Pilot Study to Evaluate the Safety and Additional Efficacy of Adding a New Chemical Entity (NCE) to Treatment with ADVAIR 250/50 Twice Daily in Patients with Chronic Obstructive Pulmonary Disease (COPD). (0 citation(s)) |
|
| ACE104325 |
phase 4 |
A randomized, open label comparative study to determine the proportion of asthma patients on SERETIDE Diskus 50/250 mcg b.i.d. achieving Total Control when given medication and compliance enhancement training compared to those receiving medication only. (0 citation(s)) |
|
| ADA103575 |
Phase 4 |
See Detailed Description (0 citation(s)) |
|
| ADA103578 |
Phase 4 |
See Detailed Description (0 citation(s)) |
|
| ADA109055 |
phase 4 |
A 52-week, Randomized, Double-Blind, Parallel-Group Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product (FSC) 250/50 mcg BID and Fluticasone Propionate (FP) DISKUS 250 mcg BID in Treatment of Subjects with Asthma (0 citation(s)) |
|
| ADA109057 |
phase 4 |
A 52-week, Randomized, Double-Blind, Parallel-Group Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product (FSC) 250/50 mcg BID and Fluticasone Propionate (FP) DISKUS 250 mcg BID in Treatment of Subjects with Asthma (0 citation(s)) |
|
| ADC105931 |
Phase 4 |
A Randomized, Double-Blind, Parallel-Group, 12-Week Study to Evaluate the Anti-Inflammatory Effect of Fluticasone Propionate/Salmeterol DISKUS 250/50mcg BID Compared with Salmeterol DISKUS 50mcg BID in Subjects with Chronic Obstructive Pulmonary Disease (COPD) (0 citation(s)) |
|
| ADERE ADULT |
Phase 4 |
A randomized, parallel group, open study to evaluate the impact of additional guidance provided by health care professionals on treatment compliance among asthmatic patients with persistent asthma (ADERE) (6 citation(s)) |
|
| ADERE PEDIATRIC 1 |
Phase 4 |
Prospective, parallel-group, randomized, open label study to evaluate the impact of additional guidance from the health professionals team on treatment compliance of children aged between 6 and 14 years old with persistent moderate or severe asthma, receiving the combination salmeterol/fluticaso ... (0 citation(s)) |
|
| C92_029 |
Phase 1 |
A study to evaluate the safety, tolerability and systemic pharmacodynamics effects of salmeterol in the salmeterol/fluticasone propionate (FP)/HFA134a inhaler. (0 citation(s)) |
|
| EPIP181 |
N/A |
A modified prescription-event monitoring study to assess the introduction of Seretide EvohalerTM into general practice in England (1 citation(s)) |
|
| FAS40008 |
Phase 4 |
An interventional three year study for asthma control - In what way and in what kind of population is it possible to get asthmatic patients free from symptoms, keep the patients in work, restore a normal lung function, diminish hyperreactivity and normalise quality of life? (2 citation(s)) |
|
| FAS40008_1 |
Phase 4 |
An interventional three year study for asthma control - In what way and in what kind of population is it possible toget asthmatic patients free from symptoms, keep the patients in work, restore a normal lung function, diminish hyperreactivity and normalise quality of life? (3 citation(s)) |
|
| FS12004 |
Phase 4 |
Seretide efficacy and safety monitoring in Slovenia (0 citation(s)) |
|
| HZA109895 |
Phase 4 |
An exploratory study to evaluate the response of salmeterol plus fluticasone propionate vs fluticasone propionate alone to experimental nasal inoculation with rhinovirus (0 citation(s)) |
|
| HZA109912 |
Phase 4 |
See Detailed Description (0 citation(s)) |
|
| IND/SEREACC/PMS |
Phase 4 |
Post Marketing Surveillance (PMS) of salmeterol and fluticasone in fixed dose combination (Seretide® Accuhaler) in the Treatment of Bronchial Asthma. (0 citation(s)) |
|
| RM2008/00607/00_1 |
N/A |
Assessment of Serious Event Outcomes in Subjects with Persistent Asthma Receiving Salmeterol-containing Products (0 citation(s)) |
|
| RPS10001 |
Phase 1 |
A phase I, monocentric, randomised, double-blind, double-dummy, cross-over study to compare the pharmacokinetics and the pharmacodynamic effects of Seretide 50 mg/250 mg bid after repeat dosing, delivered by Diskus™ versus RPID in patients with moderate asthma. (0 citation(s)) |
|
| RPS30001/SFCF3002 |
Phase 3 |
A Multicentre, Randomised, Double-Blind, Double-Dummy, Parallel-Group Study to establish Equivalence of the Fluticasone propionate/Salmeterol Combination (FSC) Product (100/50µg) via either the Reservoir Powder Inhalation Device (RPID) or via the Diskus* Inhaler over 12 Weeks in Children with Asthma (0 citation(s)) |
|
| RPS30002/SFCF3001 |
Phase 3 |
A Multicentre, Randomised, Double-Blind, Double-Dummy, Parallel-Group Study to Establish Equivalence of the Salmeterol/Fluticasone propionate Combination Product (50/250µg) via either the Reservoir Powder Inhalation Device (RPID) or via the Diskus™ Inhaler over 12 Weeks in Adolescents and Adults ... (0 citation(s)) |
|
| SAM 106538 |
Phase 4 |
Reaching Asthma control with Salmeterol/Fluticasone 50/250 µg bd combination in steroid naive or low dose inhaled corticoid steroid patients by using asthma control test (ACT) comparison of patient self rating with diary card data. (0 citation(s)) |
|
| SAM101667 |
Phase 4 |
See Detailed Description (0 citation(s)) |
|
| SAM103848 |
Phase 3 |
See Detailed Description (1 citation(s)) |
|
| SAM104926 |
Phase 4 |
See Detailed Description (0 citation(s)) |
|
| SAM108037 |
Phase 4 |
See Detailed Description (0 citation(s)) |
|
| SAM30001 |
Phase 4 |
Compliance in asthma and COPD treatment. (0 citation(s)) |
|
| SAM30002 |
Phase 3 |
A randomised, multi-centre, double blind, double-dummy, parallel-group comparison of Seretide RPID (50/100g strength) bd with budesonide BADPI 400g bd in steroid experienced adolescents and adults with reversible airways obstruction. (0 citation(s)) |
|
| SAM30003 |
Phase 3 |
A multicentre, randomised , open-label, parallel group comparison of Seretide Accuhaler TM bd with salmeterol 50mg twice daily via one Accuhaler and either fluticasone propionate 250mg or 500mg twice daily via a separate Accuhaler in adults with reversible airways disease. (1 citation(s)) |
|
| SAM30007 |
Phase 4 |
A multicentre, randomised, double-blind, controlled, parallel-group, comparative investigation of the corticosteroid-saving potential of the combination therapy fluticasone propionate and salmeterol compared with fluticasone propionate alone, given to adult asthmatic subjects, when reducing… (0 citation(s)) |
|
| SAM30008 |
Phase 3 |
A multi-centre, randomized, open-label, parallel-group, comparison study of the salmeterol/fluticasone propionate combination product via one Diskus/Accuhaler inhaler with salmeterol via one Diskus/Accuhaler inhaler and fluticasone propionate via another Diskus/Accuhaler inhaler in adults with ... (1 citation(s)) |
|
| SAM30010 |
Phase 4 |
A Randomized, Single-centre, Double-blind, Parallel-group Comparison of Seretide Accuhaler (50/250 µg Strength) bd with Fluticasone Accuhaler 250 µg bd in Subjects with Reversible Airways Obstruction (0 citation(s)) |
|
| SAM30012 |
Phase 4 |
An open study to assess the efficacy and safety of Seretide Diskus (salmeterol/fluticasone propionate 50/500mg strength) bd in subjects with reversible airways obstruction (1 citation(s)) |
|
| SAM30013 |
Phase 3 |
A 12 week, randomized, double-blind, parallel group study to compare the efficacy and safety of salmeterol/fluticasone propionate/GR106642X (25/50 µg x 2 inhalations) bid with fluticasone propionate (125 µg x 2 inhalations) bid in adolescent and adult patients with mild to moderate asthma. (0 citation(s)) |
|
| SAM30020 |
Phase 3 |
Efficacy and tolerability of the salmeterol/fluticasone 50/100 mcg combination Diskus, inhaled once daily in the evening, in comparison to the p.r.n. inhalation from the reproterol/sodium cromoglycate 0.5/ 1 mg combination MDI, as initial therapy for patients with mild asthma – a multicentre, ra ... (1 citation(s)) |
|
| SAM30021 |
Phase 3 |
A multi-centre, randomised, open-label, parallel group clinical trial to assess the efficacy and safety of Salmeterol/Fluticasone Propionate combination product (2x 25/125mg/actuation, bd) via a hydrofluoroalkane metered-doseinhaler compared… (1 citation(s)) |
|
| SAM30022 |
Phase 3 |
A phase IV, multi-centre, double-blind, double-dummy, parallel group, randomised study comparing Seretide (25/50 2 puffs bd) via the Evohaler (MDI-HFA) with Beclometasone dipropionate (200mcg 2 puffs bd) via the MDI-CFC in adolescents and adults experiencing moderate symptoms of reversible airwa ... (0 citation(s)) |
|
| SAM3802 |
Phase 4 |
An observational study to assess the health related quality of life impact of treating poorly controlled asthmatic children with Seretide 50/100mcg (0 citation(s)) |
|
| SAM40004 |
Phase 4 |
A multi-centre, randomised, double-blind, placebo-controlled parallel group study to compare the effect on airway inflammation and remodeling of treatment with salmeterol/fluticasone propionate combination product (50/100mg strength) bd via the Accuhaler inhaler, or fluticasone propionate… (2 citation(s)) |
|
| SAM40008 |
Phase 4 |
A Multicentre, Randomised, Double-Blind, Parallel Group Comparison of the Efficacy of SERETIDE* bd and Fluticasone Propionate bd (Both Via DISKUS*/ACCUHALER*, Inhaler) when Tapering the Inhaled Corticosteroid Dose in Asthmatic Adults (0 citation(s)) |
|
| SAM40010 |
Phase 4 |
A randomised, double blind, double-dummy, parallel-group, twelve week comparison of salmeterol/fluticasone propionate (FP) DISKUS/ACCUHALER 50/100mcg bd. with budesonide 200mcg bd. plus formoterol 4.5mcg bd. (both via breath-actuated dry powder inhaler [BADPI]) in Adult and Adolescent Asthmatics. (0 citation(s)) |
|
| SAM40012 |
Phase 4 |
A multicentre, randomised, double-blind, double-dummy, parallel group comparison of three treatments : 1) salmeterol/fluticasone propionate (SFC) (50/100mcg strength) bd via DISKUS/ACCUHALER inhaler, 2) fluticasone propionate 200mcg bd via DISKUS/ACCUHALER inhaler, 3) fluticasone propionate 100m ... (0 citation(s)) |
|
| SAM40027 |
Phase 4 |
Gaining Optimal Asthma ControL (GOAL): A multi-centre, stratified, randomised, double-blind, parallel-group,step-up comparison of the level of asthma control achieved with salmeterol/fluticasone propionate combinationDISKUS (ACCUHALER) dry powder inhaler compared with fluticasone propionate DISK ... (60 citation(s)) |
|
| SAM40030 |
Phase 4 |
A phase IV, multicentre, randomised, double blind, single dummy, parallel group study to compare the anti-inflammatory action of Seretide 50/100 bd via MDI with Flixotide 100mg bd via MDI plus montelukast 10mg od for 12 weeks in adults with mild to moderate asthma who are currently taking… (5 citation(s)) |
|
| SAM40031 |
Phase 4 |
A 13 month, randomised, double-blind, parallel-group comparison of the efficacy of Seretide and Flixotide(fluticasone propionate Accuhaler) when down-titrating the inhaled corticosteroid dose in asthmatic adults who have previously received SeretideTM 500/50 mg twice daily for at least 4 weeks. (0 citation(s)) |
|
| SAM40032 |
Phase 4 |
A multi-centre, open label study to demonstrate the efficacy and tolerability of Seretide Accuhaler 50/100, 50/250 or 50/500mg twice daily after substituting for budesonide or beclomethasone dipropionate in doses of 500mg up to 2000mg daily in subjects with reversible airways obstruction. (0 citation(s)) |
|
| SAM40034 |
Phase 4 |
A double-blind, randomised, parallel group, 12-week comparison of fluticasone propionate/salmeterol combination Diskus 100/50mcg BID with fluticasone propionate (FP) 250mcg BID as initial maintenance treatment in persistent asthma (Seretide Nordic Jump-Up Study) (4 citation(s)) |
|
| SAM40036 |
Phase 3 |
A 12-week multicentre, randomised, double-blind, double-dummy, parallel group study to compare the efficacy and tolerability of once daily (QD) salmeterol/fluticasone propionate combination (salm/FP) 50/100mcg at night via the DISKUS/ACCUHALER with QD budesonide (BUD) 400mcg at night via a breat ... (2 citation(s)) |
|
| SAM40040 |
Phase 4 |
A twenty-four week, randomised, double-dummy, double-blind, parallel group study to compare the rate of asthma exacerbations between SERETIDE DISKUS 50/250mg 1 inhalation bd and formoterol/budesonide Breath-Actuated Dry Powder Inhaler (BADPI) 4.5/160mg 2 inhalations bd in… (3 citation(s)) |
|
| SAM40042 |
Phase 4 |
A double-blind, double-dummy, randomised, cross-over study to compare the bronchodilator effect of SERETIDE* ACCUHALER* 50/100mcg and formoterol/budesonide combination breath-actuated dry powder inhaler 6/200mcg in subjects with asthma following a single dose and after 4 weeks of regular treatment. (1 citation(s)) |
|
| SAM40047 |
Phase 4 |
Duration of action of single inhalations of the salmeterol/ fluticasone combination product (50/250 µg) in comparison with the formoterol/ budesonide combination product (4.5/160 µg) in patients with moderate asthma - a randomised, double-blind, double-dummy, cross over study. (0 citation(s)) |
|
| SAM40048 |
Phase 4 |
Randomised, double-blind, parallel group study on the efficacy and tolerability of the salmeterol 50 mcg / fluticasone 250 mcg combination Diskus compared to the formoterol 6 mcg / budesonide 200 mcg combination turbohaler administered twice daily in patients with moderate bronchial asthma. (0 citation(s)) |
|
| SAM40049 |
Phase 4 |
A Danish, multi-centre, comparative, parallel-group study to determine whether initiation of combination treatment with Seretide™ 50/100 mg bd offers better asthma control than monotherapy with Flixotide™ 100 mg bd to adult asthmatic subjects uncontrolled on short-acting bronchodilator alone. (2 citation(s)) |
|
| SAM40056 |
Phase 4 |
See Detailed Description (5 citation(s)) |
|
| SAM40058 |
Phase 4 |
A double-blind, randomised, parallel group study to evaluate the safety and tolerability of administering two inhalations b.i.d. (double dose) of the salmeterol/fluticasone propionate combination (SERETIDE) in subjects withasthma over two weeks. (1 citation(s)) |
|
| SAM40062 |
Phase 4 |
A single-centre, single-dose, double-blind, double-dummy, placebo-controlled, randomised, three-way crossoverstudy to compare the duration of action of SERETIDE* DISKUS* 50/100mcg versus formoterol/budesonidecombination 4.5/160mcg Breath-Actuated Dry Powder Inhaler (BADPI) in subjects with asthma (1 citation(s)) |
|
| SAM40065 |
Phase 4 |
A multicenter, randomized, double-blind, parallel group, 40-week comparison of asthma control using bronchial hyperresponsiveness as an additional guide to long-term treatment in adolescents and adults receiving either fluticasone propionate/salmeterol DISKUSTM BID or fluticasone propionate DISK ... (1 citation(s)) |
|
| SAM40066 |
Phase 4 |
A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo Controlled, Parallel Group, Four-WeekStudy Assessing the Efficacy of Fluticasone Propionate Aqueous Nasal Spray 200mcg QD versus Montelukast 10mgQD in Adolescent and Adult Subjects with Asthma and Seasonal Allergic Rhinitis Who are R ... (1 citation(s)) |
|
| SAM40067 |
Phase 4 |
A multicentre, randomized, open-label, parallel-group, six-week treatment study to evaluate the efficacy and safety of Seretide (Salmeterol/Fluticasone propionate combination product) 50/100 mg strength bd via Accuhaler™ inhaler vs Pulmicort Turbuhaler™ 400 mg bd in Chinese adults with asthma (1 citation(s)) |
|
| SAM40086 |
Phase 4 |
A multicenter, randomized, double-blind, parallel group, 40-week comparison of asthma control using bronchial hyperresponsiveness as an additional guide to long-term treatment in adolescents and adults receiving either fluticasone propionate/salmeterol DISKUSTM BID or fluticasone propionate DISK ... (3 citation(s)) |
|
| SAM40088 |
Phase 4 |
Maintenance of asthma control in adults: comparison of three therapeutic strategies in patients whose asthma is controlled by a medium dose of inhaled corticosteroid and a long-acting inhaled beta2-agonist (2 citation(s)) |
|
| SAM40090 |
Phase 4 |
A Twelve Week Multi-Centre, Randomized, Double-Blind, Parallel Group, Comparative Trial of Advair 50/100 mcg Diskus Inhalation Device BID versus Flovent 250 mcg Diskus Inhalation Device BID in Adolescents and Adults with Persistent Asthma (Program of Advair Control and Effectiveness – Advair Low ... (0 citation(s)) |
|
| SAM40092 |
Phase 4 |
Effect of salmeterol/fluticasone propionate combination product on seasonal changes in airway responsiveness and exhaled nitric oxide in subjects with pollen-induced asthma. (1 citation(s)) |
|
| SAM40100 |
Phase 4 |
Comparator study to demonstrate superiority of salmeterol/fluticasone propionate 50/100mcg bd over fluticasone propionate 200mcg bd with respect to airway physiology in children treated for 6 weeks. (0 citation(s)) |
|
| SAM40101 |
Phase 4 |
A pilot single centre, randomised, double-blind, crossover study to demonstrate the superiority of Salmeterol/fluticasone propionate combination product 50/100mcg bd versus fluticasone propionate 100mcg bd when treated for two weeks with respect to activity levels in children aged 7-15 years. (0 citation(s)) |
|
| SAM40104 |
Phase 4 |
See Detailed Description (0 citation(s)) |
|
| SAM40114 |
Phase 4 |
A post-marketing surveillance study on the real world use of SFC (Salmeterol /Fluticasone Propionate Combination) in Ireland (0 citation(s)) |
|
| SAM40116 |
Phase 3 |
A 12-week multi-centre, randomised, double blind, parallel group study to compare the efficacy of salmeterol/fluticasone propionate (Seretide TM) 50/100 mcg or 50/250 mcg twice daily and fluticasone propionate (Flixotide TM) 250 mcg or 500 mcg twice daily via the Diskus TM in subjects with asthm ... (0 citation(s)) |
|
| SAM40120 |
Phase 4 |
A phase IV, multi-centre, double-blind, parallel group, randomised study comparing Seretide (50/100mcg bd) via the Evohaler (MDI-HFA) with Flixotide (250mcg bd) via the Evohaler (MDI-HFA) in asthmatics with significant smoking history (0 citation(s)) |
|
| SAM40121 |
Phase 4 |
Summary of the efficacy and safety and safety of salmeterol 50mcg and fluticasone propionate 100mcg administered in Diskus Dry Powder Inhaler twice daily in steroid experienced children with reversible airways obstruction (0 citation(s)) |
|
| SAM49071 |
Phase 4 |
See Detailed Description (0 citation(s)) |
|
| SAS10001 |
Phase 1 |
Systemic pharmacodynamic effects of salmeterol, delivered over 3 hours in a cumulative dosing series, from salmeterol/fluticasone propionate/HFA134A metered-dose inhaler (MDI) to total dose 400/2000mcg, in comparison with salmeterol/P 11/12 MDI to total dose 400mcg, and placebo, in a randomised, ... (0 citation(s)) |
|
| SAS10002 |
Phase 1 |
A Four-Period Crossover, Placebo Controlled Study to Investigate the Pharmacokinetic and Pharmacodynamic Effects of Salmeterol/Fluticasone Propionate/HFA134A via MDI in Combination Compared With Salmeterol/P11/12 and Fluticasone Propionate/P11/12 via MDI Administered Individually. (2 citation(s)) |
|
| SAS10003 |
Phase 1 |
A Double-Blind, Placebo-Controlled Four Way Crossover Study to Evaluate the Pharmacokinetics and Pharmacodynamics of Fluticasone Propionate and Salmeterol With Increasing Dose Strengths of the Fluticasone Propionate/Salmeterol/HFA134A MDI Combination Product (2 citation(s)) |
|
| SAS10005 |
Phase 1 |
A part-randomized, single-blind, placebo-controlled, five-way crossover study to assess the absolute bioavailability, relative bioavailability and comparative pharmacodynamics of fluticasone propionate from ADVAIR HFA MDI, ADVAIR DISKUS, FP CFC MDI and intravenous FP and to assess the relative b ... (2 citation(s)) |
|
| SAS10006 |
Phase 1 |
A 12-week, randomized, double-blind, placebo-controlled, 3-way crossover study in adult subjects with asthma aged 18-55 years to examine the pharmacodynamics and pharmacokinetics of fluticasone propionate (FP) administered twice daily via the DISKUS™ (FP 100mcg) and the FP/Salmeterol (SALM) comb ... (1 citation(s)) |
|
| SAS10007 |
Phase 1 |
A 16-week, randomized, double-blind, double-dummy, placebo-controlled, 4 way crossover study in adult subjects with asthma aged 18-55 years to examine the pharmacodynamics and pharmacokinetics of fluticasone propionate and salmeterol administered via FP/Salmeterol (SALM) combination product DISK ... (2 citation(s)) |
|
| SAS10013 |
Phase 1 |
An open, parallel group, repeat dose study to determine the pharmacokinetics (PK) and pharmacodynamics (PD) of salmeterol and fluticasone propionate delivered as SERETIDE DISKUS (50/250mcg twice daily [b.i.d.]) in Japanese and Caucasian asthmatic subjects. (1 citation(s)) |
|
| SAS10014 |
Phase 1 |
A study to compare the systemic pharmacodynamic effects and pharmacokinetics of SERETIDE DISKUS/ACCUHALER Inhaler (200/1000mcg) with salmeterol alone (200mcg) and fluticasone propionate alone (1000mcg) in healthy Japanese subjects (0 citation(s)) |
|
| SAS10015 |
Phase 3 |
A randomised, double-blind, double-dummy, cross-over, repeat dose study to compare the effects of SERETIDE* DISKUS (salmeterol/fluticasone propionate combination; 50/250mcg) with co-administered salmeterol (50mcg) and fluticasone propionate (250mcg) DISKUS on lung function in Japanese and Caucas ... (1 citation(s)) |
|
| SAS10016 |
Phase 1 |
A 2-week, randomized, double-blind, parallel-group study in pediatric subjects with asthma aged 4 to11 years to examine the pharmacokinetics (PK) of fluticasone propionate (FP) and salmeterol (SALM) from the FP/SALM combination product administered twice daily via the DISKUS (FP 100mcg/SALM 50mc ... (3 citation(s)) |
|
| SAS10017 |
Phase 1 |
A randomised, double-blind, single-dose, replicated 4-way crossover study to compare systemic exposure and pharmacodynamics of fluticasone propionate (FP) and salmeterol (SALM) from two batches of SALM/FP MDI with different in vitro characteristics. (4 citation(s)) |
|
| SAS10019 |
Phase 1 |
A repeat dose, randomised, double blind, 2-way crossover study to assess the safety and systemic exposure of SERETIDE/VIANI 50/50 COA compared to concurrent administration of individual Fluticasone Propionate 50 and Salmeterol 50 DISKUS inhalers in subjects aged 18 - 55 years with mild asthma (0 citation(s)) |
|
| SAS10020 |
Phase 1 |
A single dose, randomized, double-blind, 2-way crossover study to assess the safety, tolerability, pharmacodynamics and pharmacokinetic profile of SERETIDE™ 50/50 compared to concurrent administration of individual FP 50 and SALM 50 inhalers in healthy subjects aged 18 – 55 years. (0 citation(s)) |
|
| SAS104449 |
Phase 2 |
See Detailed Description (0 citation(s)) |
|
| SAS105519 |
Phase 4 |
See Detailed Description (0 citation(s)) |
|
| SAS20008 |
Phase 4 |
A 12 week open study to assess the efficacy and safety of Seretide Diskus 50/250mcg, 1 inhalation twice daily in patients with reversible airway obstruction compatible with the diagnosis of asthma. (0 citation(s)) |
|
| SAS30001 |
Phase 3 |
A Randomized, Double-Blind, Active-Controlled, Parallel-Group, 12-Week Trial Evaluating the Safety and Efficacy of the Salmeterol/Fluticasone Propionate Combination in HFA 134a MDI, 42/88mcg BID, and Salmeterol in Propellant 11/12 MDI, 42mcg BID, and Fluticasone Propionate in Propellant 11/12 MD ... (24 citation(s)) |
|
| SAS30003 |
Phase 3 |
A Stratified, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 12-Week Trial Evaluating the Safety and Efficacy of the Salmeterol/Fluticasone Propionate Combination in HFA 134a MDI, 42/88mcg BID, and Salmeterol in Propellant 11/12 MDI, 42mcg BID, Fluticasone Propionate in Propellant ... (33 citation(s)) |
|
| SAS30004 |
Phase 3 |
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group 12-Week Trial Evaluating the Safety and Efficacy of the Salmeterol/Fluticasone Propionate Combination... (14 citation(s)) |
|
| SAS30005 |
Phase 3 |
A 12-Month, Open-Label, Stratified Study to Assess the Long-Term Safety of Salmeterol/Fluticasone Propionate/HFA134a Inhalation Aerosol at Doses of 50/100mcg, 50/250mcg, and 50/500mcg BID in Adolescent and Adult Subjects with Asthma (6 citation(s)) |
|
| SAS30013 |
Phase 4 |
A study to compare the long term effects on airway inflammation of Seretide versus Flixotide in adult subjects with asthma. (0 citation(s)) |
|
| SAS30014 |
Phase 4 |
A single-centre, double-blind, randomised, cross-over study to compare the short term effects on airway inflammation after allergen challenge of salmeterol/fluticasone propionate combination product (Seretide) versus fluticasone propionate (Flixotide) in adult subjects with asthma. (3 citation(s)) |
|
| SAS30015 |
Phase 3 |
A phase IIIB, multi-centre, double-blind, parallel group, randomised study to compare the efficacy of the salmeterol/fluticasone propionate combination (25/50 mcg strength), 2 inhalations bd via HFA-MDI with beclomethasone dipropionate (BDP) 200mcg bd via metered... (11 citation(s)) |
|
| SAS30017 |
Phase 3 |
A Randomized, Double-Blind, Active-Controlled, Parallel-Group, 12-Week Trial Evaluating the Safety and Efficacy of the Salmeterol 50mcg/Fluticasone Propionate 100mcg DISKUS Combination Product BID Compared with Salmeterol 50mcg via DISKUS BID and Fluticasone Propionate 100mcg via DISKUS BID… (10 citation(s)) |
|
| SAS30018 |
Phase 3 |
Comparison of stepwise treatment of asthmatic children with Salmeterol/Fluticasone propionate combination product (Seretide®) and/or Fluticasone propionate (Flixotide®) based on PD20 methacholine and symptoms or based on symptoms only (Children Asthma Therapy Optimal) (4 citation(s)) |
|
| SAS30019 |
Phase 3 |
A multicentre, randomised, double-blind, double-dummy, parallel group study to compare the salmeterol/fluticasone propionate combination ... (3 citation(s)) |
|
| SAS30021 |
Phase 3 |
A Stratified, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 12-Week Trial Evaluating the Safety and Efficacy of the Fluticasone Propionate/Salmeterol DISKUS Combination Product 100/50mcg Once Daily Versus Fluticasone Propionate DISKUS 100mcg Once Daily and Placebo in Symptomatic ... (0 citation(s)) |
|
| SAS30022 |
Phase 3 |
A randomized, double-blind, placebo-controlled, parallel-group, 12-week trial evaluating the efficacy and safety of the fluticasone propionate/salmeterol DISKUS combination product 250/50mcg once daily versus fluticasone propionate/salmeterol DISKUS combination product 100/50mcg twice daily vers ... (11 citation(s)) |
|
| SAS30023 |
Phase 3 |
A 12-week multicentre, randomised, double-blind, placebo-controlled parallel group study to compare the efficacy and tolerability of fluticasone propionate/salmeterol combination (SERETIDE/VIANI/ADVAIR) 88/42mcg once daily in the morning with fluticasone propionate 88mcg once daily in the mornin ... (5 citation(s)) |
|
| SAS30025 |
Phase 4 |
Seretide for COntrol of REspiratory symptoms (SCORE): Switching inhaled steroids to Seretide in persistent asthma in general practice. An open label, sequential trial. (0 citation(s)) |
|
| SAS30031 |
Phase 3 |
A Randomized, Double-Blind, 12-Week Trial Evaluating the Safety of the Fluticasone Propionate/SalmeterolDISKUS Combination Product 100/50mcg BID Versus Fluticasone Propionate DISKUS 100mcg BID in Symptomatic Pediatric Subjects (4-11 Years) With Asthma (2 citation(s)) |
|
| SAS30033 |
Phase 3 |
An Open-Label, Multi-Center Study to Evaluate the Performance and Patient Satisfaction of Fluticasone Propionate/Salmeterol HFA with Counter in Asthma or COPD Subjects at Least 12 Years of Age (3 citation(s)) |
|
| SAS30035 |
Phase 3 |
A 52-week multi-centre, open-labelled, non-comparative study assessing the safety of salmeterol xinafoate/fluticasone propionate bid in adult patients with bronchial asthma (0 citation(s)) |
|
| SAS30036 |
Phase 3 |
A Double-Blind, Comparative Study to Compare Salmeterol/Fluticasone Propionate Combination Product (50/250mcg BID) with Concomitant Treatment with Fluticasone Propionate 250mcg BID Plus Sustained ReleaseTheophylline 200mg bid in Patients with Bronchial Asthma (2 citation(s)) |
|
| SAS30038 |
Phase 3 |
Clinical assessment of GW815SF (SLM/FP) for bronchial asthma - An open-labelled study of GW815SF (SLM/FP) 50/100mcg in patients with bronchial asthma (uncontrolled trial). (0 citation(s)) |
|
| SAS30039 |
Phase 3 |
A 12-week, multi-centre, randomised, double-blind, parallel-group study to compare the efficacy and tolerability of salmeterol/fluticasone propionate combination... (1 citation(s)) |
|
| SAS40002 |
Phase 4 |
A Randomised, Double-Blind, Double-Dummy, Parallel-Group Comparison of Seretide. Diskus/Accuhaler. 250/50 mg bid with Budesonide 800 mg bid plus Formoterol 12.0 mg bid (both via Breath-Actuated Dry Powder Inhaler) in Adolescent and Adult Moderate-Severe Asthmatics (2 citation(s)) |
|
| SAS40006 |
Phase 4 |
A Randomised, Double-Blind, Double-Dummy, Parallel-Group Comparison of Seretide DISKUS/ACCUHALER (50/250?g Strength) b.i.d. with Budesonide 800?g b.i.d. in Adolescents and Adults with Reversible Airways Obstruction (27 citation(s)) |
|
| SAS40007 |
Phase 4 |
A Randomised, Double-Blind, Double-Dummy, Parallel-Group Comparison of SERETIDE DISKUS/ACCUHALER (50/100?g Strength) twice daily (bid) with Budesonide 400?g bid in Adolescents and Adults with Reversible Airways Obstruction (10 citation(s)) |
|
| SAS40009 |
Phase 4 |
A multi-centre, randomised, double-blind, parallel group comparison of the salmeterol/ fluticasone propionate combination product (50/250µg) via Diskus twice daily versus fluticasone propionate (500µg) via Diskus twice daily in patients with moderate asthma (SAS 40009 local German study) (1 citation(s)) |
|
| SAS40011 |
Phase 4 |
Efficacy and Safety of salmeterol/fluticasone propionate (VIANI®) 50/250µg twice daily via Diskus in patients with mild to moderate asthma (1 citation(s)) |
|
| SAS40013 |
Phase 4 |
Can the serum level of eosinophil cationic protein (ECP) give directions for the choice between increasing the dose of fluticasone propionate or the addition of salmeterol in patients with symptomatic asthma? (0 citation(s)) |
|
| SAS40014 |
Phase 4 |
A multi-centre study examining the use of salmeterol xinafoate / fluticasone propionate via Diskus in relation to controlling asthma in moderate to severe patients: identifying risk factors contributing to an exacerbation of asthma and modification of treatment during exacerbations. (2 citation(s)) |
|
| SAS40015 |
Phase 4 |
A multicentre, randomised, double-blind, double-dummy, parallel-group, 12-week, active control comparison of the salmeterol/fluticasone propionate combination product (50/100mcg strength) bd via the DISKUS/ACCUHALERinhaler with … (11 citation(s)) |
|
| SAS40018 |
Phase 4 |
A Multi-Center, Randomized, Double-Blind, Double Dummy, Parallel-Group, 12 Week Active Control Comparison of Salmeterol/Fluticasone Propionate Combination Product (50/100mcg BID) via the DISKUS inhaler with Fluticasone Propionate (100mcg BID) via the DISKUS plus Oral Montelukast (10mg QD) in Adu ... (7 citation(s)) |
|
| SAS40019 |
Phase 4 |
A randomised, double blind, parallel group comparison of the effect of the salmeterol/fluticasone propionate combination product (50/250 mcg strength) bd via the Diskus inhaler with placebo bd via the Diskus inhaler in young adults who are in clinical remission of allergic asthma (2 citation(s)) |
|
| SAS40020 |
Phase 4 |
A Randomized, Double-Blind, Double-Dummy, Parallel Group, 12-Week Comparative Trial of Salmeterol/Fluticasone Propionate Combination Product 50/100mcg BID Via the DISKUS Inhaler Versus Oral Montelukast 10mg QD in Adolescents and Adults with Persistent Asthma (23 citation(s)) |
|
| SAS40021 |
Phase 4 |
A Randomized, Double-Blind, Double-Dummy, Parallel Group, 12-Week Comparative Trial of Salmeterol/Fluticasone Propionate Combination Product 50/100mcg BID Via the DISKUS Inhaler Versus OralMontelukast 10mg QD in Adolescents and Adults with Persistent Asthma (17 citation(s)) |
|
| SAS40023 |
Phase 4 |
A multi-centre, prospective study of Viani 50/250µg twice daily via Diskus in patients with mild to moderate asthma Viani and Diskus are registered trademarks of the GlaxoSmithKline group of companies. (1 citation(s)) |
|
| SAS40024 |
Phase 4 |
A Randomized, Double-Blind, Parallel-Group Study Evaluating the Protective Effects of the Fluticasone Propionate/Salmeterol Combination Product (FSC, 100/50mcg BID via DISKUS) Against Bronchospasms Induced by Activity as Measured by Exercise Challenge Testing in Adolescent and Adult Subjects who ... (3 citation(s)) |
|
| SAS40025 |
Phase 4 |
A Randomized, Double-Blind, Parallel-Group Study Evaluating the Protective Effects of the Fluticasone Propionate/Salmeterol Combination Product (FSC 250/50mcg BID via DISKUS) Against Bronchospasms Induced by Activity as… (2 citation(s)) |
|
| SAS40026 |
Phase 4 |
A randomized, double-blind, parallel group, comparative trial of fluticasone propionate/salmeterol combination product 100/50mcg DISKUS inhaler BID versus fluticasone propionate 250mcg DISKUS inhaler BID in adolescents and adults with moderate persistent asthma. (6 citation(s)) |
|
| SAS40027 |
Phase 4 |
A Randomized, Double-Blind, Parallel Group, Comparative Trial of Fluticasone Propionate/Salmeterol Combination Product 100/50mcg DISKUS Inhaler BID versus Fluticasone Propionate 250mcg DISKUS Inhaler BID in Adolescents and Adults with Moderate Persistent Asthma (7 citation(s)) |
|
| SAS40028 |
Phase 4 |
An open-label, 12-week study to evaluate the effects of a corticosteroid-sparing dose of salmeterol/fluticasone propionate combination product 50/100mcg BID via the DISKUS inhaler on airway inflammation, airway remodeling, and bronchial hyperresponsiveness in adults with persistent asthma. (1 citation(s)) |
|
| SAS40030 |
Phase 4 |
A study to investigate switching from usual therapy to the salmeterol/ fluticasone (50/500 mcg) combination Diskus, followed by a reduction of inhaled steroid dosage in patients with moderate to severe asthma (1 citation(s)) |
|
| SAS40032 |
Phase 4 |
A randomised, parallel-group study of Viani (Salmeterol 50 mcg plus Fluticasone 250 mcg b.i.d.) inhaled from the Diskus® inhaler compared to Budesonide (800-1600 mcg) inhaled from Turbuhaler® plus a long-acting inhaled beta-2-agonist, in subjects with asthma
(0 citation(s)) |
|
| SAS40036 |
Phase 4 |
A Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel Group, 16-Week Comparison of Asthma Control in Adolescents and Adults Receiving Either Fluticasone Propionate/Salmeterol DISKUS Combination Product 100/50mcg BID, Fluticasone Propionate DISKUS 100mcg BID, Salmeterol Xinafoate DISKUS ... (0 citation(s)) |
|
| SAS40037 |
Phase 4 |
A Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel Group, 16-Week Comparison of Asthma Control in Adolescents and Adults Receiving Either Fluticasone Propionate/Salmeterol DISKUS™ Combination Product 100/50mcg BID, Fluticasone Propionate DISKUS™ 100mcg BID, Salmeterol Xinafoate DISK ... (0 citation(s)) |
|
| SAS40039 |
Phase 4 |
Fluticasone propionate 250 µg plus salmeterol 50 µg (Seretide 50/250 µg bd) combined in a single inhaler (Diskus) in symptomatic patients with mild to moderate asthma previously not treated by maintenance therapy with inhaled corticosteroids and/or long acting beta agonists in adults and childre ... (0 citation(s)) |
|
| SAS40066 |
Phase 4 |
A Randomized, Open-Label, Crossover Pilot Trial, Assessing Patient Preference for ADVAIR DISKUS 100/50 BID (Fluticasone Propionate/Salmeterol Combination Product 100/50mcg) versus Singulair QD (Montelukast 10mg) in Subjects - 15 years of age with Persistent Asthma. (0 citation(s)) |
|
| SAS40067 |
Phase 4 |
Gaining asthma control with Seretide 50/500 in patients with moderate to severe persistent asthma in general practice. (0 citation(s)) |
|
| SAS40068 |
Phase 4 |
A 24 week, multicentre, randomized, double-blind, parallel group trial to compare the efficacy and tolerability of salmeterol/fluticasone propionate (ADVAIR) DISKUS inhalation ... (3 citation(s)) |
|
| SCO104925 |
Phase 4 |
See Detailed Description (0 citation(s)) |
|
| SCO107227 |
phase 4 |
A 12 month open-label randomized parallel group study to investigate the influence of salmeterol xinafoate/fluticasone propionate either in fixed combination or separately via Diskus inhalers on the course of the disease and frequency of exacerbations in subjects with severe and very severe COPD. (0 citation(s)) |
|
| SCO30002 |
Phase 3 |
A Multicentre, Randomised, Double-Blind, Parallel Group, Placebo-Controlled Study to Compare the Efficacy and Safety of Inhaled Salmeterol/Fluticasone Propionate Combination Product 25/250 µg Two Puffs Bd and Fluticasone Propionate 250µg Two Puffs Bd Alone, All Administered Via Metered Dose Inh ... (0 citation(s)) |
|
| SCO30003 |
Phase 3 |
See Detailed Description (22 citation(s)) |
|
| SCO30005 |
Phase 3 |
A 13-week, double-blind, parallel group, multi-centre study to compare the bronchial anti-inflammatory activity of the combination of salmeterol/fluticasone propionate 50/500mcg twice daily compared with placebo twice daily in patients with Chronic Obstructive Pulmonary Disease (COPD) (9 citation(s)) |
|
| SCO30006 |
Phase 3 |
A randomised, double-blind, parallel-group study to investigate the protective effect of the combination of fluticasone and salmeterol (500/50µg bid via the DISKUS) compared with salmeterol (50µg bid via the DISKUS) on the incidence of moderate to severe exacerbations in patients with severe chr ... (2 citation(s)) |
|
| SCO30008 |
Phase 4 |
A single centre, randomised, double-blind, double dummy, parallel group 3-week study to compare the effect of the salmeterol/fluticasone propionate combination 50/500mcg bd via the DISKUS™/ACCUHALER™ inhaler with tiotropium bromide 18 mcg od via the Handihaler inhaler on mucociliary clearance ra ... (0 citation(s)) |
|
| SCO40002 |
Phase 4 |
SCO400002/SER9602/COSMIC: One year withdrawal of fluticasone propionate after three months treatment with combined salmeterol/fluticasone propionate in COPD: the COSMIC study. (1 citation(s)) |
|
| SCO40011 |
Phase 4 |
A Randomized, Double-Blind, Double-Dummy, Parallel-Group, Comparative Clinical Trial Evaluating Fluticasone Propionate/Salmeterol 250/50mcg BID via DISKUS to Ipratropium Bromide/Albuterol Sulfate (36mcg/206mcg QID) Inhalation Aerosol in Subjects with Chronic Obstructive Pulmonary Disease (COPD) (2 citation(s)) |
|
| SCO40012 |
Phase 4 |
A Randomized, Double-Blind, Double-Dummy, Parallel-Group, Comparative Clinical Trial Evaluating Fluticasone Propionate/Salmeterol (250/50mcg BID via DISKUS) to Ipratropium Bromide/Albuterol Sulfate (36mcg/206mcg QID) Inhalation Aerosol in Subjects with Chronic Obstructive Pulmonary Disease (COPD) (10 citation(s)) |
|
| SCO40030 |
Phase 4 |
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Clinical Trial Evaluating the Effect of the Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID via DISKUS and Salmeterol 50mcg BID via DISKUS on Lung Hyperinflation in Subjects with Chronic Obstructive Pulmonary Dise ... (1 citation(s)) |
|
| SCO40034 |
Phase 4 |
A multicentre, randomised, double-blind, double dummy, parallel group 12-week exploratory study to compare the effect of the salmeterol/fluticasone propionate combination product (SERETIDE™) 50/500mcg bd via the DISKUS™/ACCUHALER™ inhaler with tiotropium bromide 18 mcg od via the Handihaler inha ... (0 citation(s)) |
|
| SCO40036 |
Phase 4 |
See Detailed Description (5 citation(s)) |
|
| SCO40041 |
Phase 4 |
A Randomized, Double-Blind, Parallel-Group Clinical Trial Evaluating the Effect of the fluticasone propionate/salmeterol Combination Product 250/50mcg BID via DISKUS versus salmeterol 50mcg BID via DISKUS on Bone Mineral Density in Subjects with Chronic Obstructive Pulmonary Disease (COPD) (0 citation(s)) |
|
| SCO40043 |
Phase 4 |
See Detailed Description (1 citation(s)) |
|
| SCO40055 |
Phase 3 |
See Detailed Description (0 citation(s)) |
|
| SFA100314 |
Phase 4 |
A Stratified, Multicenter, Randomized, Double-Blind, Parallel Group, 4-Week Comparison of Fluticasone Propionate/Salmeterol DISKUS Combination Product 100/50mcg BID versus Fluticasone Propionate DISKUS 100mcg BID in Pediatric and Adolescent Subjects with Activity-Induced Bronchospasm (1 citation(s)) |
|
| SFA100316 |
Phase 4 |
A Stratified, Multicenter, Randomized, Double-Blind, Parallel Group, 4-Week Comparison of Fluticasone Propionate/Salmeterol DISKUS Combination Product 100/50mcg BID versus Fluticasone Propionate DISKUS 100mcg BID in Pediatric and Adolescent Subjects with Activity-Induced Bronchospasm (0 citation(s)) |
|
| SFA103153 |
Phase 4 |
A Multicenter, Randomized, Double-Blind, Parallel Group, 52-Week Comparison of Asthma Control and Measures of Airway Inflammation in Subjects of African Descent Receiving Fluticasone Propionate/Salmeterol 100/50mcg DISKUS® BID or Fluticasone Propionate 100mcg DISKUS® BID Alone (1 citation(s)) |
|
| SFA106484 |
Phase 3 |
A randomized, double-blind, parallel group study evaluating the safety of fluticasone propionate/salmeterol 100/50mcg HFA (2 inhalations of 50/25mcg) twice daily compared with fluticasone propionate 100mcg HFA (2 inhalations of 50mcg) twice daily in subjects 4-11 years of age with persistent asthma (0 citation(s)) |
|
| SFCA3002 |
Phase 3 |
A Randomized, Double-Blind, Parallel-Group Trial Evaluating Safety and Efficacy of Salmeterol 50mcg BID and Fluticasone Propionate 100mcg BID Individually and in Combination and Placebo in Subjects with Asthma. (9 citation(s)) |
|
| SFCA3003 |
Phase 3 |
A Randomized, Double-Blind, Parallel-Group Trial Evaluating Safety and Efficacy of Salmeterol 50mcg BID and Fluticasone Propionate 250mcg BID Individually and in Combination and Placebo in Subjects with Asthma. (19 citation(s)) |
|
| SFCA3006 |
Phase 3 |
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial Evaluating the Safety and Efficacy of the DISKUS Formulations of Salmeterol (SAL) 50mcg BID and Fluticasone Propionate (FP) 500mcg BID Individually and in Combination as Salmeterol 50mcg/Fluticasone Propionate 500mcg BID (SFC 5 ... (4 citation(s)) |
|
| SFCA3007 |
Phase 3 |
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial Evaluating the Safety and Efficacy of the DISKUS Formulations of Salmeterol (SAL) 50mcg BID and Fluticasone Propionate (FP) 250mcg BID Individually and in Combination as Salmeterol 50mcg/Fluticasone Propionate 250mcg BID (SFC 5 ... (5 citation(s)) |
|
| SFCB1001 |
Phase 1 |
A study to evaluate the safety, tolerability and systemic pharmacodynamic effects of salmeterol in the salmeterol/FP DISKUS™ inhaler (2 citation(s)) |
|
| SFCB1002 |
Phase 1 |
A study to evaluate the safety, tolerability, pharmacokinetics and systemic pharmacodynamic effects of fluticasone propionate in the salmeterol/fluticasone propionate DISKUS™ inhaler (0 citation(s)) |
|
| SFCB1004 |
Phase 1 |
The systemic pharmacodynamic effects and pharmacokinetics of salmeterol and fluticasone propionate when given alone and in combination, after repeat dosing from DISKUS™ inhalers in healthy volunteers (3 citation(s)) |
|
| SFCB1005 |
Phase 1 |
The systemic pharmacodynamic effects and pharmacokinetics of salmeterol and fluticasone propionate when given together, from either a single or two separate DISKUS™ inhalers, in single doses (0 citation(s)) |
|
| SFCB3017 |
Phase 3 |
A multicentre randomised, double-blind, double-dummy, parallel group comparison of the salmeterol/fluticasone propionate combination product (50/100mcg strength) BID via one DISKUS/ACCUHALER inhaler with salmeterol 50mcg BID via one DISKUS/ACCUHALER inhaler and fluticasone propionate 100mcg BID ... (12 citation(s)) |
|
| SFCB3018 |
Phase 3 |
A multicentre randomised, double-blind, double-dummy, parallel group six-month comparison of the salmeterol/fluticasone propionate combination product (50/250mcg strength) BID via one DISKUS/ACCUHALER inhaler with salmeterol 50mcg BID via one DISKUS/ACCUHALER inhaler and fluticasone propionate 2 ... (4 citation(s)) |
|
| SFCB3019 |
Phase 3 |
A multicentre randomized, double-blind, double-dummy, parallel-group comparison of the salmeterol/fluticasone propionate combination product (50/500mcg strength) BD via one DISKUS/Accuhaler inhaler with salmeterol 50mcg BD via one DISKUS/Accuhaler and fluticasone propionate 500mcg BD via another ... (13 citation(s)) |
|
| SFCB3020 |
Phase 3 |
A Multicentre, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Comparison of the Salmeterol/Fluticasone Propionate Combination Product (50/100mcg strength) BD Via One DISKUS/ACCUHALER Inhaler with Salmeterol 50mcg BD Via One DISKUS/ACCUHALER and Fluticasone Propionate 100mcg BD Via a Sec ... (2 citation(s)) |
|
| SFCB3022 |
Phase 3 |
A multicentre, randomised, double-blind, double-dummy, parallel-group, three-month comparison of the salmeterol/fluticasone propionate combination product (2x25/50mcg strength) bd via the pressurised metered dose inhaler with salmeterol/fluticasone propionate combination product (1x50/100mcg str ... (9 citation(s)) |
|
| SFCB3023 |
Phase 3 |
A multicentre, randomised, double-blind, double-dummy, parallel-group, three-month comparison of the salmeterol/fluticasone propionate combination product (2x25/250mcg strength) bd via the pressurised metered dose inhaler with salmeterol/fluticasone propionate combination product (1x50/500mcg st ... (9 citation(s)) |
|
| SFCB3024 |
Phase 3 |
A multicentre, randomised, double-blind, parallel group, placebo-controlled study to compare the efficacy and safety of the salmeterol/FP combination product at a strength of 50/500mcg bd with salmeterol 50mcg bd alone and FP 500mcg bd alone, delivered via the DISKUS™/ACCUHALER™, in the treatmen ... (15 citation(s)) |
|
| SFCF4001 |
Phase 4 |
Uncontrolled asthma in adults: comparison of combination FP/salmeterol (administered via Diskus) with doubling the dosage of inhaled corticosteroid + long acting ?2-mimetic or adding long acting ?2-mimetic to corticosteroid previously inhaled. (0 citation(s)) |
|
| SFCF4002 |
Phase 4 |
Asthma controlled by Seretide in adults with persistent moderate asthma : efficacy in preventing exacerbations and quality of life (1 citation(s)) |
|
| SFCF4006 |
Phase 4 |
Study of control of moderate to severe asthma with Seretide in general practice. (0 citation(s)) |
|
| SFCF4007 |
Phase 4 |
Comparison of the efficacy and safety of Seretide and beclomethasone dipropionate plus montelukast in asthma. (0 citation(s)) |
|
| SFCF4020 |
Phase 4 |
Asthma control: evaluation in adults during treatment with Seretide (0 citation(s)) |
|
| SFCF4021 |
Phase 4 |
Research of predictive factors for the response to Seretide® in chronic obstructive pulmonary disease patients with FEV1<50% (0 citation(s)) |
|
| SLGA5021 |
Phase 4 |
A randomized, double-blind clinical trial comparing the efficacy and safety of salmeterol xinafoate 42mcg b.i.d.* plus fluticasone propionate 88mcg b.i.d.* versus fluticasone propionate 220mcg b.i.d.* alone in subjects with asthma not well controlled on fluticasone propionate 88mcg b.i.d.* (0 citation(s)) |
|
| SLGA5022 |
Phase 4 |
A randomised, double-blind clinical trial comparing the efficacy and safety of salmeterol xinafoate 42mcg b.i.d.* plus fluticasone propionate 88mcg b.i.d.* versus fluticasone propionate 220mcg b.i.d.* alone in subjects with asthma not well controlled on fluticasone propionate 88mcg b.i.d.* (1 citation(s)) |
|
| VIA-001 |
Phase 4 |
Cost-effectiveness of a combination of Fluticasone Propionate and Salmeterol Xinafoate in comparison with conventional therapies of bronchial asthma (VIANI Real life). (0 citation(s)) |
|
| VIA-002 |
Phase 4 |
Viani® forte Discus® Post Marketing Surveillance Study. (0 citation(s)) |
|
| WEUKBRE1157 / EPI40472 |
N/A |
Assessment of the Risk of Pneumonia among COPD Patients on Seretide or Inhaled Corticosteroids in the UK primary care (0 citation(s)) |
|
| WEUKSTV1076 |
N/A |
Assessment of incidence of pneumonia among COPD patients with or without exposure to inhaled steroids in the General Practice Research Database (GPRD) (0 citation(s)) |
|
